Market closed

Repligen/$RGEN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Ticker

$RGEN
Sector
Health Care
Trading on
NASDAQ

Industry

Life Sciences Tools & Services
Headquarters
Waltham, United States

Employees

-
Website
www.repligen.com

Repligen Metrics

BasicAdvanced
$8.9B
-
-$0.04
0.96
-

$8.9B

0.96

$211.13

$113.50

469K

10.442

8.425

32.742

37.398

1.20%

0.60%

-0.40%

13.835

4.4

13.69

67.449

-4.46%

-101.86%

2.59%

-73.79%

What the Analysts think about Repligen

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Repligen stock.

Repligen Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Repligen Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Repligen News

AllArticlesVideos
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1 week ago
Repligen Launches the CTech™ SoloVPE® PLUS System

Repligen Launches the CTech™ SoloVPE® PLUS System

GlobeNewsWire·1 week ago
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGEN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Repligen stock?

Repligen (RGEN) has a market cap of $8.9B as of January 15, 2025.

What is the P/E ratio for Repligen stock?

The price to earnings (P/E) ratio for Repligen (RGEN) stock is 0 as of January 15, 2025.

Does Repligen stock pay dividends?

No, Repligen (RGEN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Repligen dividend payment date?

Repligen (RGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Repligen?

Repligen (RGEN) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.